Prediction of Sensitivity to Olaparib in Patients With Unresectable or Metastatic Locally Advanced HER2-Negative Breast Cancer With BRCA1, BRCA2, PALB2, RAD51C, or RAD51D Mutations or Low RAD51 Levels: RADIOLA ASSAY
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: SOLTI
- Phase: II
- Execution start: 15/11/2021
- End of execution: 28/02/2024
- IP: ISABEL BLANCAS LOPEZ-BARAJAS